At the news
? BULLISHIMPACT 7/10 8-K filed Apr 29, 2026 at 07:50 ET
AbbVie reported Q1 2026 adjusted EPS of $2.65, above the prior company guidance range of $2.56-$2.60, and revenue of $15.002B (+12.4% YoY). The company raised full-year 2026 adjusted EPS guidance from $13.96-$14.16 to $14.08-$14.28, driven by strong growth in immunology (Skyrizi +30.9%, Rinvoq +23.3%) and neuroscience (+26.0%).
- Q1 2026 net revenue $15.002B, +12.4% YoY reported, +10.3% operational
- Q1 2026 adjusted diluted EPS $2.65, +7.7% YoY; GAAP EPS $0.39, -45.8% YoY
- Full-year 2026 adjusted diluted EPS guidance raised to $14.08-$14.28 from $13.96-$14.16
- Immunology revenue $7.290B (+16.4%), neuroscience $2.875B (+26.0%)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access